LYN101

LYN101 is an investigational biologic fusion protein being developed as a first-in-human therapy to improve bone health and reduce osteoporotic fracture risk in individuals with low bone mass, including postmenopausal women with osteoporosis risk factors. It is administered subcutaneously and is being evaluated in a randomized, double-blind, placebo-controlled Phase 1 trial assessing single and multiple ascending doses in healthy volunteers and postmenopausal women with low bone mass, with endpoints including safety, pharmacokinetics, pharmacodynamics, bone turnover markers, and bone mineral density. Early clinical information characterizes LYN101 as a long-acting, subcutaneously delivered biologic targeting bone remodeling pathways to increase bone formation and/or decrease bone resorption, but detailed target identity and molecular mechanism have not yet been publicly disclosed.